Depakote is known for suppression of bone marrow and a variety of other hematologic adverse effects such as: lymphocytosis, thrombocytopenia, leukopenia, eosinophilia, anemia, hypofibrinogenemia, and altered bleeding time; all of which are related to the body's production of blood cells in the bone marrow.
It is important for patients receiving Depakote to have baseline blood analysis prior to beginning Depakote and to have the therapeutic level of Depakote monitored routinely and for the patient's bloodwork to be monitored routinely for signs of decreases in platelets and other blood cells. If bone marrow suppression or other blood cell disorders are identified, Depakote should be discontinued and alternate medication pursued.
As for any litigation regarding bone marrow suppression, I doubt any class actions suits exists as the drug company has never denied the potential risk of bone marrow suppression or denied the more serious adverse effects on the liver. It is up to the physician to monitor the patient receiving Depakote and to know which patients should NEVER receive Depakote (children <18 months, pregnant women or nursing mothers, persons with hepatic disease). I will search for any class action suits, though, if you'll tell us why you asked.
EC